Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Jenkins (Nottingham, United Kingdom), I. Noth (Charlottesville, Virginia, United States of America), M. Selman (Mexico City, Mexico), V. Cottin (Lyon, France), Y. Nishioka (Tokushima, Japan), J. Song (Seoul, Republic of Korea), A. Prasse (Hannover, Germany), E. White (Ann Arbor, Michigan, United States of America), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Biberach an der Riss, Germany), K. Rohr (Ingelheim am Rhein,, Germany), S. Stowasser (Ingelheim am Rhein,, Germany), T. Maher (London, United Kingdom). Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK trial. 5187

Member's Comments

No comment yet.

Related content which might interest you: Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia Year: 2019 Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia Year: 2020 Investigating effects of nintedanib on biomarkers of ECM turnover in patients with IPF: the INMARK study Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018 Does excluding subjects with features similar to IPF affect the results of the INBUILD trial of nintedanib? Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 Effect of roflumilast on lung function: Results from 180-days study in subjects With severe COPD Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Expression of apoptotic markers in lung tissue of COPD patients: preliminary results Source: Eur Respir J 2006; 28: Suppl. 50, 748s Year: 2006 Changes in biomarkers with nintedanib and sildenafil in subjects with IPF in the INSTAGE trial: subgroup analysis by right heart dysfunction (RHD) Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis Year: 2020 The effect of nintedanib compared to pirfenidone on proliferation of lung fibroblasts from patients with IPF Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Safety and tolerability of nintedanib in patients with fibrosing interstitial lung diseases: pooled data from four trials Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021 Patterns of discontinuation in patients with IPF treated with open-label nintedanib: data from INPULSIS-ON Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials Source: Eur Respir J 2016; 47: 243-253 Year: 2016 The effect of treatment with pirfenidone on death or lung transplantation in patients with idiopathic pulmonary fibrosis (IPF): Analysis of outcomes in the CAPACITY (CAP) trials Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Transplantation of alveolar type II cells in pulmonary fibrosis: experimental studies, MSC in IPF trials Source: International Congress 2014 – Targeting lung fibrosis: from bench to bedside Year: 2014 The magnitude of pirfenidone treatment effect in patients with idiopathic pulmonary fibrosis (IPF): A pooled analysis of outcomes in the CAPACITY (CAP) studies Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Prospective phase 1 open clinical trial to study the safety of adipose derived mesenchymal stem cells (ADMSCs) in COPD and combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response ? A meta-analysis. Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019 Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019